WO2005020876A2 - Pharmaceutical composition, method of manufacturing and therapeutic use thereof - Google Patents
Pharmaceutical composition, method of manufacturing and therapeutic use thereof Download PDFInfo
- Publication number
- WO2005020876A2 WO2005020876A2 PCT/CZ2004/000053 CZ2004000053W WO2005020876A2 WO 2005020876 A2 WO2005020876 A2 WO 2005020876A2 CZ 2004000053 W CZ2004000053 W CZ 2004000053W WO 2005020876 A2 WO2005020876 A2 WO 2005020876A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- oxaliplatin
- animal origin
- alcoholic
- pharmaceutical composition
- freeze
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/555—Heterocyclic compounds containing heavy metals, e.g. hemin, hematin, melarsoprol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Definitions
- the invention relates to a pharmaceutical composition which is prepared by freeze-drying and contains oxaliplatin as the active component and a pharmaceutically acceptable carrier, application of this composition reducing the risk of viral contamination, especially by causers of animal spongiform encephalopathy.
- Oxaliplatin (named according to the INN nomenclature as oxaliplatinum) has been prepared for the first time in the optically pure form in 1978 by isolation from a mixture of isomers [ J. Clin. Hematol. Oncol. 1977, 7(1), 197-210].
- Oxaliplatin is chemically the ⁇ trans-(-)-l,2-cyclohexanediamine ⁇ -(oxalato)platinum(II) complex of formula I
- Oxaliplatin is a cytostatic agent used in treatment of testicular and ovarial tumors, malignant melanoma, bronchogenic carcinoma and especially of metastazing colon carcinoma in combination with fiuoropyrimidines. In comparison with the hitherto used cisplatinum, oxaliplatin exhibits lower nefrotoxicity and a broader spectrum of antitumor activity. Oxaliplatin is generally applied in doses 100 to 135 mg/m 2 in the form of 2 to 6 hours' infusion. The infusion solution is prepared by dilution of the final drug form with 5% aqueous solution of glucose.
- this dry powdery composition contains a carrier consisting of lactose which ensures the cohesion of the dry oxaliplatin matrix formed by freeze-drying in vacuo and prevents its cracking, which otherwise would result in escape of part of the oxaliplatin from vials in which the freeze-drying takes place.
- lactose carrier which is an animal product
- the substantial drawback of the hitherto used lactose carrier, which is an animal product is the risk of viral contamination of the pharmaceutical composition by viruses that may be present in lactose.
- Lactose hitherto employed in oxaliplatin pharmaceutical compositions, exhibits very good cryoprotective effects and its replacement with another suitable carrier under preservation of properties of oxaliplatin lyophilizate and economy of the freeze-drying process so far has not been satisfactorily solved.
- the pharmaceutical composition according to the present invention prepared by freeze-drying in vacuo, that contains oxaliplatin as the active component together with a pharmaceutically acceptable carrier, the said composition being characterized in that it contains at least one alcoholic sugar of non-animal origin as a carrier, the ratio of oxaliplatin to this alcoholic sugar or alcoholic sugars of non-animal origin being 1:3 to 1:7 by weight.
- the pharmaceutical composition according to the invention contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a ratio 1 :5 by weight.
- the preferred alcoholic sugar of non-animal origin is mannitol.
- the present invention also relates to the method of manufacturing of the above mentioned pharmaceutical composition, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of no-animal origin in a weight ratio 1:3 to 1:7 with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume equal to at most 60 % of the available vial volume, whereupon the content of the vial is cooled to 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left aside at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
- the invention also relates to the above mentioned pharmaceutical composition for application in treatment of tumors sensitive to oxaliplatin.
- the pharmaceutical composition according to this invention affords a clear solution which contains neither undissolved material nor turbidity and which is thus particularly suitable for parenteral application.
- the composition according to the invention can be readily prepared, is highly stable and its application does not represent any risk of viral contamination.
- the method according to the present invention solves problems that would occur in the case of mere replacement of lactose by mannitol without changing the existing mode of working with lactose.
- the lyophilizate often escapes from the vials and the glass vials crack as the result of increased mechanical tension due to the changing volume of the freezed solution, which is particularly manifested by falling away of the vial bottom during the freeze-drying procedure. It has been found that the temperature mode of the freezing procedure according to the invention significantly eliminates the mentioned vial cracking in the course of the freeze- drying procedure.
- the total concentration of oxaliplatin and of at least one alcoholic sugar in the aqueous solution before the freeze-drying must be 2.8 to 3.2 % by weight.
- the vials can be filled with the sterile solution of oxaliplatin and mannitol in the mentioned weight ratio in a volume up to 60 % of the available vial volume without change of the lyophilizate quality, without escape of the lyophilizate from the vials, and without cracking of the vials, which represents a very advantageous solution from the viewpoint of utilization of capacity of the freeze-drying equipment.
- the pharmaceutical composition according to the invention is particularly suitable for application in treatment of tumors sensitive to oxaliplatin.
- the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C.
- the frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
- the obtained lyophilizate has a white compact form and contains 0.8 % by weight of water. Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
- the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C.
- the frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
- Example 3 This Example studies the stability of the pharmaceutical composition prepared in Example 1 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 1 below.
- Example 4 This Example studies the stability of the pharmaceutical composition prepared in Example 2 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 2 below.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Biochemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Virology (AREA)
- Molecular Biology (AREA)
- Oncology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
Abstract
The invention relates to a pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, wherein the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7. The invention also relates to the method of manufacturing of said composition and to the use of this composition in the treatment of tumors sensitive to oxaliplatin.
Description
Pharmaceutical Composition, Method of Manufacturing and Therapeutic Use Thereof
Field of the Invention
The invention relates to a pharmaceutical composition which is prepared by freeze-drying and contains oxaliplatin as the active component and a pharmaceutically acceptable carrier, application of this composition reducing the risk of viral contamination, especially by causers of animal spongiform encephalopathy.
Background of the Invention
Oxaliplatin (named according to the INN nomenclature as oxaliplatinum) has been prepared for the first time in the optically pure form in 1978 by isolation from a mixture of isomers [ J. Clin. Hematol. Oncol. 1977, 7(1), 197-210]. Oxaliplatin is chemically the {trans-(-)-l,2-cyclohexanediamine}-(oxalato)platinum(II) complex of formula I
Oxaliplatin is a cytostatic agent used in treatment of testicular and ovarial tumors, malignant melanoma, bronchogenic carcinoma and especially of metastazing colon carcinoma in combination with fiuoropyrimidines. In comparison with the hitherto used cisplatinum, oxaliplatin exhibits lower nefrotoxicity and a broader spectrum of antitumor activity. Oxaliplatin is generally applied in doses 100 to 135 mg/m2 in the form of 2 to 6 hours' infusion. The infusion solution is prepared by dilution of the final drug form with 5% aqueous solution of glucose.
Within the framework of the prior art there was described a series of liquid drug forms of oxaliplatin based on its aqueous solutions which however for their insufficient stability so far have not found application. The cause of this instability is the known fact that oxaliplatin
hydrolytically decomposes under formation of toxic platinum aquacomplexes. The only stable drug form of oxaliplatin known so far is a powder composition obtained by freeze-drying in vacuo (lyophilization). Beside oxaliplatin, this dry powdery composition contains a carrier consisting of lactose which ensures the cohesion of the dry oxaliplatin matrix formed by freeze-drying in vacuo and prevents its cracking, which otherwise would result in escape of part of the oxaliplatin from vials in which the freeze-drying takes place. The substantial drawback of the hitherto used lactose carrier, which is an animal product, is the risk of viral contamination of the pharmaceutical composition by viruses that may be present in lactose. Recently, reduction of the risk of such viral contamination, especially of transfer of animal spongiform encephalopathy, represents a current problem concerning most drug forms that contain auxiliary components of animal, particularly bovine origin. Lactose, hitherto employed in oxaliplatin pharmaceutical compositions, exhibits very good cryoprotective effects and its replacement with another suitable carrier under preservation of properties of oxaliplatin lyophilizate and economy of the freeze-drying process so far has not been satisfactorily solved.
Summary of the Invention
The above-mentioned desired replacement of the lactose carrier with another carrier which in principle eliminates the mentioned risk of viral contamination is solved by the pharmaceutical composition according to the present invention, prepared by freeze-drying in vacuo, that contains oxaliplatin as the active component together with a pharmaceutically acceptable carrier, the said composition being characterized in that it contains at least one alcoholic sugar of non-animal origin as a carrier, the ratio of oxaliplatin to this alcoholic sugar or alcoholic sugars of non-animal origin being 1:3 to 1:7 by weight.
Preferably, the pharmaceutical composition according to the invention contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a ratio 1 :5 by weight.
In a pharmaceutical composition according to the invention, the preferred alcoholic sugar of non-animal origin is mannitol.
The present invention also relates to the method of manufacturing of the above mentioned pharmaceutical composition, characterized in that a sterile aqueous solution of oxaliplatin and
of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of no-animal origin in a weight ratio 1:3 to 1:7 with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume equal to at most 60 % of the available vial volume, whereupon the content of the vial is cooled to 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left aside at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
Finally, the invention also relates to the above mentioned pharmaceutical composition for application in treatment of tumors sensitive to oxaliplatin.
After dissolution in a suitable pharmaceutically acceptable solvent, the pharmaceutical composition according to this invention affords a clear solution which contains neither undissolved material nor turbidity and which is thus particularly suitable for parenteral application. The composition according to the invention can be readily prepared, is highly stable and its application does not represent any risk of viral contamination.
The method according to the present invention solves problems that would occur in the case of mere replacement of lactose by mannitol without changing the existing mode of working with lactose. During workup of solutions in which lactose is simply replaced with mannitol, the lyophilizate often escapes from the vials and the glass vials crack as the result of increased mechanical tension due to the changing volume of the freezed solution, which is particularly manifested by falling away of the vial bottom during the freeze-drying procedure. It has been found that the temperature mode of the freezing procedure according to the invention significantly eliminates the mentioned vial cracking in the course of the freeze- drying procedure. Thus, it was found that in order to achieve an optimal freeze-drying rate the total concentration of oxaliplatin and of at least one alcoholic sugar in the aqueous solution before the freeze-drying must be 2.8 to 3.2 % by weight. Further, it was found that the vials can be filled with the sterile solution of oxaliplatin and mannitol in the mentioned weight ratio in a volume up to 60 % of the available vial volume without change of the lyophilizate quality, without escape of the lyophilizate from the vials, and without cracking of the vials, which represents a very advantageous solution from the viewpoint of utilization of capacity of the freeze-drying equipment.
For its properties, the pharmaceutical composition according to the invention is particularly suitable for application in treatment of tumors sensitive to oxaliplatin.
In the following part of the description the invention will be explained in detail using individual examples of execution, that are only illustrative, without limiting in any way the scope of the invention.
Examples
Example 1
Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C in 70 kg of water. The obtained solution is sterilized by filtration through a 0.22 μm filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 50 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 0.8 % by weight of water. Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 2
Under GMP conditions, 0.50 kg of oxaliplatin (pharmacopoeia quality) and 2.50 kg of mannitol (pharmacopoeia quality) are gradually dissolved at 20 to 25 °C in 70 kg of water. The obtained solution is sterilized by filtration through a 0.22 μm filter and filled into colourless clear vials for antibiotics of the first hydrolytic class, type 20 H (Saint Gobain Desjonqueres) the amount of the solution corresponding to 100 mg of the dissolved active component per vial. The filled vials are equipped with stoppers for freeze-drying and placed into a freeze-drying chamber, pre-cooled to 5 °C. After thermal equilibration of the solution in the vial with the environment, the solution in the vial is slowly freezed (linear temperature drop of 0.2 °C/min) to the final temperature of -40 °C. The frozen solution is left at this temperature for 4 h, whereupon it is subjected to freeze-drying in vacuo.
The obtained lyophilizate has a white compact form and contains 1.0 % by weight of water. Dissolution of the obtained material gives a clear solution, in accord with Ph. Eur. Art. 2.2.1.
Example 3 This Example studies the stability of the pharmaceutical composition prepared in Example 1 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 1 below.
Table 1
The percentages given in Table 1 are % by weight.
Example 4 This Example studies the stability of the pharmaceutical composition prepared in Example 2 when stored at 40 °C and 75% relative humidity. The obtained results are given in Table 2 below.
Table 2
The percentages given in Table 2 are % by weight.
Claims
1. A pharmaceutical composition prepared by freeze-drying in vacuo, containing oxaliplatin as the active component and a pharmaceutically acceptable carrier, characterized in that the carrier is at least one alcoholic sugar of non-animal origin, the weight ratio of oxaliplatin to the alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin being 1:3 to 1:7.
2. The pharmaceutical composition according to Claim 1, characterized in that it contains oxaliplatin and an alcoholic sugar of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:5.
3. The pharmaceutical composition according to Claims l or2, characterized in that the alcoholic sugar of non-animal origin is mannitol.
4. A method of manufacturing of pharmaceutical composition according to Claim 1, characterized in that a sterile aqueous solution of oxaliplatin and of at least one alcoholic sugar of non-animal origin, containing oxaliplatin and an alcoholic suger of non-animal origin or alcoholic sugars of non-animal origin in a weight ratio 1:3 to 1:7, with total concentration of the mentioned compounds 2.8 to 3.2 % by weight, is introduced into a vial in a volume amount equal to at most 60 vol% of the available vial volume, whereupon the content of the vial is cooled to a temperature of 2 to 8 °C, then freezed under linear temperature drop of 0.1 to 0.5 °C/min to a final temperature of -35 to -45 °C, left at this temperature for 1 to 6 hours and then subjected to freeze-drying in vacuo.
5. The pharmaceutical composition according to any of Claims 1 to 3 for use in the treatment of tumors sensitive to oxaliplatin.
Priority Applications (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2006525029A JP2007504177A (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, process for its production and therapeutic use |
| EP04762305A EP1663106A2 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
| CA002537610A CA2537610A1 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
| US10/569,866 US20060275331A1 (en) | 2004-08-31 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CZ20032367A CZ300795B6 (en) | 2003-09-02 | 2003-09-02 | Pharmaceutical composition and process for its preparation |
| CZPV2003-2367 | 2003-09-02 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| WO2005020876A2 true WO2005020876A2 (en) | 2005-03-10 |
| WO2005020876A3 WO2005020876A3 (en) | 2005-06-09 |
Family
ID=34256928
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/CZ2004/000053 Ceased WO2005020876A2 (en) | 2003-09-02 | 2004-08-31 | Pharmaceutical composition, method of manufacturing and therapeutic use thereof |
Country Status (6)
| Country | Link |
|---|---|
| EP (1) | EP1663106A2 (en) |
| CA (1) | CA2537610A1 (en) |
| CZ (1) | CZ300795B6 (en) |
| PL (1) | PL366975A1 (en) |
| RU (1) | RU2329052C2 (en) |
| WO (1) | WO2005020876A2 (en) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089709A3 (en) * | 2007-01-22 | 2009-06-18 | Pliva Lachema As | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer |
| CZ300664B6 (en) * | 2007-01-22 | 2009-07-15 | Pliva-Lachema A. S. | Sterile liquid pharmaceutical composition and process for preparing thereof |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8810173D0 (en) * | 1988-04-29 | 1988-06-02 | Norsk Hydro As | Pharmaceutical compositions with anti-cancer activity & method for treatment of cancer |
| WO1994012193A1 (en) * | 1992-11-24 | 1994-06-09 | Debiopharm S.A. | Cisplatinum/oxaliplatinum combination |
| FR2740686B1 (en) * | 1995-11-03 | 1998-01-16 | Sanofi Sa | STABLE LYOPHILIZED PHARMACEUTICAL FORMULATION |
| GB9804013D0 (en) * | 1998-02-25 | 1998-04-22 | Sanofi Sa | Formulations |
| EP2921180B1 (en) * | 1999-02-22 | 2019-08-14 | University of Connecticut | Albumin-free factor VIII formulations |
| ES2206288T3 (en) * | 1999-08-30 | 2004-05-16 | Debiopharm S.A. | STABLE PHARMACEUTICAL PREPARATION OF OXYLIPLATINE FOR PARENTERAL ADMINISTRATION. |
| DE10314377A1 (en) * | 2003-03-28 | 2004-10-07 | Stada Arzneimittel Ag | Pharmaceutical composition useful for tumor therapy comprises water, oxaliplatin and an acid other than oxalic acid |
-
2003
- 2003-09-02 CZ CZ20032367A patent/CZ300795B6/en not_active IP Right Cessation
-
2004
- 2004-04-05 PL PL04366975A patent/PL366975A1/en not_active Application Discontinuation
- 2004-08-31 CA CA002537610A patent/CA2537610A1/en not_active Abandoned
- 2004-08-31 RU RU2006110563/15A patent/RU2329052C2/en active
- 2004-08-31 WO PCT/CZ2004/000053 patent/WO2005020876A2/en not_active Ceased
- 2004-08-31 EP EP04762305A patent/EP1663106A2/en not_active Withdrawn
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008089709A3 (en) * | 2007-01-22 | 2009-06-18 | Pliva Lachema As | Oxaliplatin pharmaceutical composition with alcoholic sugar-based buffer |
| CZ300664B6 (en) * | 2007-01-22 | 2009-07-15 | Pliva-Lachema A. S. | Sterile liquid pharmaceutical composition and process for preparing thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1663106A2 (en) | 2006-06-07 |
| CZ300795B6 (en) | 2009-08-12 |
| RU2329052C2 (en) | 2008-07-20 |
| CA2537610A1 (en) | 2005-03-10 |
| CZ20032367A3 (en) | 2005-04-13 |
| PL366975A1 (en) | 2005-03-07 |
| WO2005020876A3 (en) | 2005-06-09 |
| RU2006110563A (en) | 2006-08-10 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP1658848B1 (en) | Formulations comprising ecteinascidin and a disaccharide | |
| JP4890732B2 (en) | Paclitaxel / liposome composition for cancer treatment and method for producing the same | |
| CN1154654A (en) | A pharmaceutically stable oxaliplatin preparation | |
| CA3120505C (en) | Methods for treatment of diseases | |
| DK157168B (en) | PROCEDURE FOR THE PREPARATION OF PHARMACEUTICAL PREPARATIONS BASED ON CIS PLATIN (II) DIAMINDICHLORIDE | |
| JP2022081630A (en) | Freeze-dried composition containing benzoazepine compound | |
| JP2016534060A (en) | Process for producing a lyophilized pharmaceutical composition having a content of mitomycin C | |
| CN101530393B (en) | Clindamycin phosphate lipidosome freeze-dried preparation | |
| CN102512378B (en) | Stable and safe oxiracetam pharmaceutical composition for injection | |
| FI86800C (en) | Process for preparing an injectable, ready-to-use, sterile, pyrogen-free anthracyclic glycoside solution | |
| WO2015102315A1 (en) | Pharmaceutical composition not containing antioxidant and preparation method therefor | |
| CN102258531A (en) | Medicinal composition containing adenosine cyclophosphate and meglumine and preparation method thereof | |
| US5750131A (en) | Ifosfamide lyophilizate preparations | |
| US20060275331A1 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| NO169324B (en) | PROCEDURE FOR THE MANUFACTURING OF DRY MATERIALS ACQUIRED BY AFFICIENT AND SUITABLE FOR THE PREPARATION OF STABLE SUSPENSIONS | |
| CN104414977A (en) | Artesunate and L-arginine composition for injection and preparation method thereof | |
| CS226002B2 (en) | Method of stabilizing aqueous sterile platinum cis-diamine-dichloride solution | |
| EP1663106A2 (en) | Pharmaceutical composition, method of manufacturing and therapeutic use thereof | |
| CN101254174B (en) | Freeze-dried injection containing carbazochrome sodium sulfonate and method of preparing the same | |
| RU2449791C2 (en) | Lyophilised injected pharmaceutical compostion of semisynthetic alkaloids vinca and carbohydrates, stable at room temperature | |
| JP2012501331A (en) | Camphosfamide formulation and method for producing the same | |
| CN111671912A (en) | Composition containing cobamamide, freeze-dried powder, preparation method thereof and injection medicine | |
| JP2007504177A (en) | Pharmaceutical composition, process for its production and therapeutic use | |
| CN103417474A (en) | Calcium dibutyacyladenosine cyclophosphate-containing composition for injection | |
| JPH0321252A (en) | Cysplatin high tension liquid |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DPEN | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed from 20040101) | ||
| WWE | Wipo information: entry into national phase |
Ref document number: 2006275331 Country of ref document: US Ref document number: 10569866 Country of ref document: US |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2537610 Country of ref document: CA Ref document number: 2006525029 Country of ref document: JP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2004762305 Country of ref document: EP |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 2006110563 Country of ref document: RU |
|
| WWP | Wipo information: published in national office |
Ref document number: 2004762305 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 10569866 Country of ref document: US |